Last reviewed · How we verify
Placebo of Hydroxyzine
This is a placebo control arm and contains no active pharmaceutical ingredient; it produces no pharmacological effect.
This is a placebo control arm and contains no active pharmaceutical ingredient; it produces no pharmacological effect. Used for Control arm in phase 3 clinical trial of hydroxyzine.
At a glance
| Generic name | Placebo of Hydroxyzine |
|---|---|
| Sponsor | University Hospital, Brest |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo of hydroxyzine is an inert formulation used as a control in clinical trials to compare against the active hydroxyzine drug. It allows researchers to isolate the true therapeutic effect of hydroxyzine from placebo response. The placebo itself has no mechanism of action.
Approved indications
- Control arm in phase 3 clinical trial of hydroxyzine
Common side effects
Key clinical trials
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) (PHASE1)
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (PHASE3)
- Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial (PHASE3)
- Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study (PHASE3)
- A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) (PHASE4)
- A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Hydroxyzine CI brief — competitive landscape report
- Placebo of Hydroxyzine updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI